Improved Closure of Patent Ductus Arteriosus With High Doses of Ibuprofen
Authors:
- 4 February 2012
- journal article
- clinical trial
- Published by Springer Nature in Pediatric Cardiology
- Vol. 33 (4) , 586-590
Abstract
The patent ductus arteriosus (PDA) is associated with various complications of prematurity. Cyclooxygenase-inhibitors are the first-line intervention for closure of the PDA. However, the rates of PDA closure still are unsatisfactory. Therefore, an individual trial was performed by changing the strategy for treating neonates with ibuprofen to induce the closure of PDA. In a retrospective study, patients receiving 20, 10, and 10 mg/kg bodyweight ibuprofen (group 1) were compared by chart review with those receiving 10, 5, 5 mg/kg (group 2). The rate of PDA closure, the incidence of side effects related to the use of ibuprofen, and the need for surgical intervention for closure of the PDA were analyzed. A higher rate of closure after three doses in group 1 could be observed (60.9 vs 52.6%; p = 0.75), which was not significant but indicated a clear positive trend. If closure of the PDA was unsuccessful, intravenous ibuprofen was continued for an additional 2 days. After 5 days, 91.3% of PDA in group 1 was closed compared with 68.4% PDA in group 2. In summary, only 8.7% of the group 1 neonates needed surgical closure of PDA after insufficient medicamentous closure compared with 31.6% in group 2 (p = 0.25). Although not statistically significant, a clear positive trend for using the higher-dose medication can be seen. More work dealing with the limitations of a retrospective study must be done. Based on the data from this study, high-dose ibuprofen seems able to increase the rate of effective medicamentous PDA closure without any further unwanted side effects.Keywords
This publication has 26 references indexed in Scilit:
- Patent Ductus Arteriosus of the Preterm InfantPediatrics, 2010
- Failure of Ductus Arteriosus Closure Is Associated With Increased Mortality in Preterm InfantsPediatrics, 2009
- An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic studyBritish Journal of Clinical Pharmacology, 2008
- Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants2008
- Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infantsCochrane Database of Systematic Reviews, 2007
- Systematic Review: Intravenous Ibuprofen in Preterm NewbornsSeminars in Perinatology, 2006
- Association between Fluid Intake and Weight Loss during the First Ten Days of Life and Risk of Bronchopulmonary Dysplasia in Extremely Low Birth Weight InfantsThe Journal of Pediatrics, 2005
- A Comparison of Ibuprofen and Indomethacin for Closure of Patent Ductus ArteriosusNew England Journal of Medicine, 2000
- Risk Factors for Chronic Lung Disease in the Surfactant Era: A North Carolina Population-based Study of Very Low Birth Weight InfantsPediatrics, 1999
- Factors determining reopening of the ductus arteriosus after successful clinical closure with indomethacinThe Journal of Pediatrics, 1995